Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P13569: Variant p.Thr665Ser

Cystic fibrosis transmembrane conductance regulator
Gene: CFTR
Feedback?
Variant information Variant position: help 665 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Threonine (T) to Serine (S) at position 665 (T665S, p.Thr665Ser). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and polar (T) to small size and polar (S) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In CF; uncertain significance; no effect on glycan maturation and channel activity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 665 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 1480 The length of the canonical sequence.
Location on the sequence: help MGCDSFDQFSAERRNSILTE T LHRFSLEGDAPVSWTETKKQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         MGCDSFDQFSAERRNSILTETLHRFSLEGDAPVSWTETKKQ

Gorilla                       MGCDSFDQFSAERRNSILTETLRRFSLEGDAPVSWTETKKQ

                              MGYDSFDQFSPERRNSIITETLRRFSLEGDAAVPWNETKKQ

Rhesus macaque                MGYDSFDQFSAERRNSILTETLRRFSLEGDAPVSWTETKKQ

Chimpanzee                    MGCDSFDQFSAERRNSILTETLRRFSLEGDAPVSWTETKKQ

Mouse                         MGYDTFDQFTEERRSSILTETLRRFSVD-DSSAPWSKP-KQ

Rat                           MGYDTFDQFTEERRSSILTETLRRFSVD-DASTTWNKA-KQ

Pig                           MGYDTFDQFTAERRNSIITETLRRFSLEGDASVSWNETKKQ

Bovine                        MGCDTFDQFTAERRNSIITETLRRFSLEGDTSVSWNETKKP

Rabbit                        MGYDSFDQFSAERRNSILTETLRRFSLEGDASISWNDTRKQ

Sheep                         MGCDTFDQFTAERRNSIITETLRRFSLEGDTSVSWNETKKP

Horse                         MGYDSFDQFSAERRNSILTETLRRFSLEGDATVSWNETKKQ

Xenopus laevis                IG---FDHFNAERRNSIITETLRRCSIDSDPSAVRNEVKNK

Zebrafish                     LGLEAYDNISAERRCSILTETLHRVSVDESAGM---QPERS

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 1480 Cystic fibrosis transmembrane conductance regulator
Topological domain 359 – 858 Cytoplasmic
Region 654 – 831 Disordered R region
Modified residue 660 – 660 Phosphoserine; by PKA
Modified residue 670 – 670 Phosphoserine; by PKA
Alternative sequence 606 – 1480 Missing. In isoform 3.
Helix 655 – 669



Literature citations
Distribution of CFTR mutations in cystic fibrosis patients of Tunisian origin: identification of two novel mutations.
Messaoud T.; Verlingue C.; Denamur E.; Pascaud O.; Quere I.; Fattoum S.; Elion J.; Ferec C.;
Eur. J. Hum. Genet. 4:20-24(1996)
Cited for: VARIANT CF SER-665; Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator.
Vankeerberghen A.; Wei L.; Jaspers M.; Cassiman J.-J.; Nilius B.; Cuppens H.;
Hum. Mol. Genet. 7:1761-1769(1998)
Cited for: CHARACTERIZATION OF VARIANTS CF PHE-601; SER-610; THR-613; GLY-614; THR-618; SER-619; GLN-620; PRO-620; ARG-628; PRO-633; SER-665; LEU-693 AND LYS-822; CHARACTERIZATION OF VARIANTS CBAVD ASP-622; MET-766; GLY-792; GLY-800 AND MET-807; CHARACTERIZATION OF VARIANT THORACIC SARCOIDOSIS LYS-826;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.